VERTEX PHARMACEUTICALS INC / MA
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
VRTX$550.87+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive
Condensed Consolidated Statements of Comprehensive Income
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net income | $653.6 | $1,082.9 | $2,784.8 | $2,762.1 |
| Other comprehensive income (loss): | ||||
| Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $7.0, $(1.0), $20.7 and $(7.7), respectively | (24.8) | 3.5 | (73.4) | 27.4 |
| Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(10.7), $(9.4), $(45.8) and $70.3, respectively | 38.2 | 33.5 | 162.8 | (248.7) |
| Foreign currency translation adjustment | (4.7) | (0.4) | (16.3) | 29.0 |
| Total other comprehensive income (loss) | 8.7 | 36.6 | 73.1 | (192.3) |
| Comprehensive income | $662.3 | $1,119.5 | $2,857.9 | $2,569.8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.